Related Experiment Video
Updated: Dec 10, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Calcinosis in Systemic Sclerosis: Updates in Pathophysiology, Evaluation, and Treatment
Carrie Richardson1,2, Anna Plaas3, John Varga4
1Rush University Medical Center, Chicago, IL, USA. carrie_richardson@rush.edu.
Purpose Of Review:
Calcinosis is a common complication of systemic sclerosis with no known effective pharmacologic therapy. We reviewed the literature regarding systemic sclerosis-related calcinosis as well as other disorders of biomineralization in order to identify targets of future study for calcinosis.
Recent Findings:
Patients with systemic sclerosis-related calcinosis demonstrate systemic abnormalities in mineralization pathways, including decreased levels of the mineralization inhibitor inorganic pyrophosphate. Insights from other mineralization disorders suggest that local and systemic phosphate metabolism pathways involving the ABCC6, ENPP1, and NT5E genes play a critical role in regulation of ectopic calcification. Knockout models of these genes may lead to an appropriate murine model for study of calcinosis. Poly(ADP-ribose) polymerase (PARP) enzymes may also play a critical role in hydroxyapatite nucleation and warrant future study in systemic sclerosis. Study of local and systemic mineralization pathways, particularly phosphate metabolism pathways and PARP enzymes, should provide greater insight into the pathogenesis of systemic sclerosis-related calcinosis.
Insights
Systemic sclerosis-related calcinosis involves abnormal mineralization pathways. Future research on phosphate metabolism and PARP enzymes may reveal effective therapies for this common complication.
Area of Science:
- Biomineralization
- Systemic Sclerosis Pathogenesis
- Ectopic Calcification
Background:
- Calcinosis is a frequent complication of systemic sclerosis (SSc).
- Currently, no effective pharmacologic treatments exist for SSc-related calcinosis.
- Patients with SSc-calcinosis exhibit systemic mineralization pathway abnormalities, including reduced inorganic pyrophosphate levels.
Purpose of the Study:
- To review literature on SSc-related calcinosis and other biomineralization disorders.
- To identify potential therapeutic targets for calcinosis.
- To explore the role of phosphate metabolism and PARP enzymes in SSc-calcinosis pathogenesis.
Main Methods:
- Literature review of systemic sclerosis-related calcinosis.
- Analysis of other disorders of biomineralization.
- Investigation of genetic and enzymatic pathways involved in ectopic calcification.
Main Results:
- Systemic abnormalities in mineralization pathways are observed in SSc-related calcinosis.
- Decreased inorganic pyrophosphate levels are noted.
- Phosphate metabolism pathways (involving ABCC6, ENPP1, NT5E genes) and Poly(ADP-ribose) polymerase (PARP) enzymes are implicated in ectopic calcification.
Conclusions:
- Insights from other mineralization disorders highlight the role of phosphate metabolism.
- Knockout models of ABCC6, ENPP1, and NT5E may provide suitable murine models for calcinosis research.
- Further study of phosphate metabolism and PARP enzymes is crucial for understanding SSc-calcinosis pathogenesis and developing treatments.
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Skeleton and Calcium Homeostasis
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Nephrotic Syndrome I : Introduction

